secwatch.observer — SEC 8-K summary
======================================

Issuer:     IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK:        0001425205
Form:       8-K
Filed at:   2023-07-13T23:59:59+00:00
Accession:  0001104659-23-080770
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iovance Biotherapeutics closes $172.5M public offering of 23M shares at $7.50/share
--------------------------------------------------------------------------------

- Closed underwritten public offering of 23,000,000 shares at $7.50 per share.
- Gross proceeds $172.5M; net proceeds expected ~$161.4M after discounts and expenses.
- Proceeds to fund lifileucel commercial launch prep, iCTC manufacturing, and clinical programs.
- Full exercise of underwriters' option to purchase an additional 3 million shares.
- Goldman Sachs & Co. LLC and Jefferies LLC acted as joint lead book-running managers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1425205/000110465923080770/0001104659-23-080770-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1425205/000110465923080770/tm2320915d5_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-080770

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer